29 October 2026

Why reactive workplace benefits are failing cancer patients

Improvements in cancer treatment might mean your employee benefits are no longer cost-effective, or practical, but a focus shift to emotional wellbeing could help.

Advances in diagnosis, treatment and personalised care mean more people are surviving cancer and continuing to live and work for longer.

Today, around one in two people diagnosed with cancer will survive for ten years or more, compared with approximately one in four in the early 1970s. At the same time, diagnosis rates continue to rise, driven by an ageing population, greater awareness and improved screening and diagnostic capabilities.

For employers, this creates a new challenge. Cancer is no longer an event affecting only a handful of employees. It is increasingly becoming a workforce-wide issue that impacts long-term healthcare costs, benefit spend, absence, productivity and employee wellbeing.

As more people live and work with cancer, organisations are having to consider whether their existing approaches to support remain fit for purpose.

Growing cost of cancer for private healthcare schemes

When discussing cancer in the workplace, attention often focuses on treatment costs. The total cost of diagnosis and treatment of cancer can have a substantial impact on private healthcare schemes:

Diagnosis: access to specialist consultations, diagnostic imaging and investigations can all generate significant healthcare expenditure.
Treatment: following diagnosis, treatment costs to the employer can escalate rapidly. While traditional treatments such as surgery, chemotherapy and radiotherapy remain common, advances in medical science have led to increasing use of targeted therapies, immunotherapies and personalised treatment plans. These innovations are delivering better outcomes for many patients, but they are also increasing the cost and complexity of cancer care. For employers funding private medical insurance (PMI), this presents a growing challenge. Individual cancer claims can exceed £100,000 and, in some cases, significantly more. A small number of high-cost claims can have a disproportionate impact on scheme experience, renewal premiums and long-term affordability.

The result is growing pressure on healthcare budgets at a time when many organisations are already facing rising claims costs across multiple areas of employee health.

Impact beyond healthcare costs

The true cost of cancer extends well beyond the healthcare claim itself.

Employees may experience periods of absence while undergoing investigations, treatment or recovery. Even where individuals remain at work, productivity can be affected by fatigue, side effects, anxiety and uncertainty.

Colleagues and managers can be affected too, with teams often needing to absorb additional workloads, while managers can face difficult conversations around support, adjustments and return-to-work planning.

There can also be a significant emotional and psychological impact. Concerns around diagnosis, treatment outcomes, finances and family responsibilities can contribute to increased stress and mental health challenges throughout the cancer journey.

In addition, cancer can also drive utilisation across multiple employee benefits:

Income protection schemes may experience claims relating to extended absence from work.
Critical illness policies may be triggered by diagnosis.
Group life insurance benefits may become relevant in the most serious cases.
Occupational health support, employee assistance programmes and wellbeing services may all see increased demand.

Viewed through this wider lens, cancer is not simply a healthcare issue. It is a workforce issue with implications across an organisation's entire people strategy.

Why traditional approaches are becoming unsustainable

Historically, employer support and benefits have been focused on providing protection at or after diagnosis, typically through access to treatment or by supporting ongoing income for unwell employees through an income protection scheme. More recently, a greater range of wellbeing and financial support during and after treatment is being made available.

These benefits remain important, but they are inherently reactive. They support employees once cancer has been diagnosed, rather than addressing earlier stages of the journey.

This approach overlooks three important factors:

There are preventative measures, lifestyle interventions and awareness initiatives that may help reduce the likelihood of some cancers developing in the first place.
Earlier recognition of symptoms and faster access to care can significantly improve treatment outcomes and reduce further complexities.
There is likely to be a significant impact on productivity through increased stress and uncertainty, often before a formal diagnosis is made.

As cancer increasingly affects a wider demographic of the workforce, this reactive model is becoming less effective, both from a cost management perspective and an employee wellbeing perspective.

From reactive benefits to proactive support

A modern cancer strategy should support employees across the entire journey, from prevention through to recovery and return to work.

Prevention and awareness: Investing in and encouraging employees to engage with preventative health measures and recognise potential symptoms earlier. Strategies such as offering health assessments/screening, reviewing overall workforce data and creating targeted wellbeing initiatives can also help identify emerging risks and focus resources where they may have the greatest impact.
Earlier intervention: Faster access to diagnostics and specialist advice can help reduce delays and improve outcomes. Equally important is supporting employees who are experiencing symptoms or health concerns before a diagnosis has been confirmed. Many employers already have valuable resources available through existing benefits. Occupational health services, vocational rehabilitation support attached to income protection schemes and insurer-added value services can all play an important role in helping employees navigate the early stages of their journey.
Support throughout the journey: Increasingly, specialist providers are helping employers support employees through every stage of cancer care. It is increasingly recognised that cancer support is not only about funding treatment. It is about helping employees navigate the wider physical, emotional and practical challenges that accompany a diagnosis. Services such as Perci Health, Reframe Cancer and similar programmes provide access to multidisciplinary support, including psychological wellbeing, rehabilitation, practical guidance and return-to-work assistance.
Rethinking how high-cost claims are financed: Finally, employers may need to explore innovative approaches to managing the financial impact of exceptionally high-cost cases. As treatment costs continue to rise, organisations should consider whether traditional funding arrangements remain appropriate. Potential solutions may include risk-sharing arrangements, reinsurance structures or complementary benefits such as critical illness cover that can provide additional financial support when employees need it most.

While these approaches will not be suitable for every organisation, they reflect a broader trend towards finding more sustainable ways to manage increasingly complex healthcare risks.